Learning objectives

Upon completion of this program, participants will be able to :

  • Understand when to use targeted therapy in patients suffering from lung cancer with EGFR mutations;
  • Differentiate between the existing EGFR inhibitors in lung cancer treatments;
  • Recognize osimertinib’s place in therapy for EGFR T790M mutation-positive lung cancer;
  • Know the efficacy, the proper usage and safety of osimertinib;
  • Counsel patients on the proper use of osimertinib and the management of possible side effects.

Click here to watch this new CCCEP accredited webinar. If you are in Quebec, you can watch the French version accredited by the OPQ here.